ABOUT GARDP FOUNDATION

The Global Antibiotic Research & Development Partnership (GARDP Foundation) is a not-for profit global health organization registered in Geneva, Switzerland. GARDP’s mission is to accelerate the development and access of treatments for drug-resistant bacterial infections. It does so by forging public-private partnerships all over the world to develop and expand access to treatments for serious bacterial infections and sepsis in adults, children and newborns, as well as sexually transmitted infections (STIs).
GARDP Foundation responds to the crisis in antimicrobial resistance. In 2015, the World Health Assembly, the decision-making body of the World Health Organization (WHO), adopted
the Global Action Plan on Antimicrobial Resistance. The following year, to deliver on this plan, WHO and the Drugs for Neglected Diseases initiative created GARDP. In 2018, the GARDP Foundation was legally established as an independent entity.
Since then, GARDP Foundation has developed a portfolio of antibiotic treatments that targets WHO priority pathogens, priority diseases and key populations/regions that are especially affected by drug resistance. It is also pioneering new access initiatives with innovator, manufacturing and distribution partners.
As of 2024, the GARDP team consists of about 100 people who collectively share extensive cross-sector R&D and access experience. They work with the key public and private sector stakeholders and partners, such as the research and development community, donors, industry and implementing countries

PROJECT BACKGROUND & PURPOSE OF THE RFP

2.1. Background to project
In Brazil, gonorrhea cases may be captured differently across clinical care, laboratory, public health reporting, community-based services, informal or self-treatment pathways, and in populations with limited engagement in healthcare.
Published and unpublished evidence on gonorrhea epidemiology, barriers to care, vulnerable populations, and STI service delivery in Brazil remains limited. For example, considering the data available until now, the SenGono network, which monitors gonorrhea prevalence and antimicrobial resistance, covers only the male population with urethritis, and geographical coverage is limited across the country.
Consolidating data across different settings and understanding the gaps is critical to determine which populations are disproportionately affected and have adequate access to care, to define the research needed to better understand these inequities, and to guide interventions that improve health outcomes. This is particularly relevant as Brazil prepares for the future
introduction of a single dose oral treatment, which experts at the February 2026 workshop in Florianopolis identified as potentially beneficial for vulnerable populations.
An effective methodology should combine an integrative review, data systems mapping, and evidence triangulation tailored to STI surveillance in populations that are partly or fully outside formal healthcare systems. The aim is not only to synthesize existing evidence on gonorrhea diagnostic and treatment in Brazil, but to identify structural gaps in current surveillance and reporting systems and develop a roadmap for future surveillance and patient journey studies.
A useful framing is to position the work as an “integrative evidence ecosystem review” rather than a conventional literature review alone, especially as it shall also cover analysis of unpublished databases and datasets.

2.2. Purpose of RFP
GARDP seeks to commission a consultancy firm to assess available evidence and data systems related to gonorrhea diagnosis and treatment, service delivery, and access to STI care in Brazil among vulnerable and underserved populations. For that purpose, we open an RFP for an integrative review that allows for identification, consolidation, and cross-checking of existing data sources (published and unpublished) to guide the design of subsequent surveillance, patient-journey and implementation studies. This involves aligning information across available data sources—such as surveillance, laboratory, and routine reporting systems—to identify what data is being collected and where important gaps remain.

If you are interested to receive the complete documentation, please send an email to: RFP_Procurement@gardp.org.

Due/closing date: November 12th, 2026